Loss of sigma binding sites in the CA1 area of the anterior hippocampus in Alzheimer's disease correlates with CA1 pyramidal cell loss.
The densities of [3H]1,3-di-o-tolylguanidine ([3H]DTG) binding to sigma binding sites in the CA1 stratum pyramidale region in 7 hippocampi affected by Alzheimer's disease, were compared with densities in 7 normal hippocampi. There was an average reduction of 26% in [3H]DTG binding in this area, which was correlated with an average 29% pyramidal cell loss in the same region. These results are consistent with experiments in animals indicating that sigma binding sites are preferentially associated with the somata of large cells.
Jansen
K L
KL
Oxford University, SmithKline Beecham Centre for Applied Neuropsychobiology, University Department of Clinical Pharmacology, Radcliffe Infirmary, UK.
Faull
R L
RL
Storey
P
P
Leslie
R A
RA
D000368:Aged; D000544:Alzheimer Disease / Q000378:metabolism* / Q000473:pathology*; D001345:Autoradiography; D001665:Binding Sites; D016923:Cell Death; D005260:Female; D006146:Guanidines / Q000378:metabolism; D006624:Hippocampus / Q000378:metabolism* / Q000473:pathology*; D006801:Humans; D008297:Male; D017480:Receptors, sigma / Q000378:metabolism*; D012016:Reference Values; D014018:Tissue Distribution
D006146:Guanidines; D017480:Receptors, sigma; C050232:1,3-ditolylguanidine